Results 11 to 20 of about 19,637 (185)
Ezetimibe: An Unusual Suspect in Angioedema
Case Reports in Medicine, 2020 We describe a case of new onset angioedema likely due to Ezetimibe therapy in an elderly patient with a prior history of drug-induced bradykinin reactions who had been on the medication for multiple years.
Tiffany Lu, Tarundeep Grewal
doaj +2 more sources
Ezetimibe Anticancer Activity via the p53/Mdm2 Pathway
BiomedicinesBackground: Ezetimibe is used to treat cardiovascular disease as it blocks the sterol transporter Niemann-Pick C1-Like 1 (NPC1CL1) protein. However, recent evidence indicates that Ezetimibe inhibits several cancers indirectly by reducing circulating ...
Charmy Twala +4 more
doaj +2 more sources
Drug Design, Development and Therapy, 2017 Chang Hee Kim,1 Hyungmi An,2 Sung Hye Kim,3 Dongseong Shin4 1Department of Urology, Gachon University Gil Medical Center, Incheon, 2Department of Statistics, Seoul National University, Seoul, 3Clinical Development, Navipharm Co., Ltd., Suwon ...
Kim CH, An H, Kim SH, Shin D
doaj +1 more source
Species Differences in Ezetimibe Glucuronidation
MetabolitesBackground: Peclinical and clinical studies have revealed that ezetimibe, an approved cholesterol-absorption inhibitor, is rapidly and extensively metabolized to a more potent metabolite, ezetimibe glucuronide.
Shalom Emmanuel +5 more
doaj +2 more sources
Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition. [PDF]
PLoS ONE, 2015 Ezetimibe, as a cholesterol absorption inhibitor, has been shown protecting against atherosclerosis when combined with statin. However, side by side comparison has not been made to evaluate the beneficial effects of ezetimibe alone versus statin. Herein,
Chunmiao Tie +6 more
doaj +2 more sources
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia [PDF]
Vascular Health and Risk Management, 2010 Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse21Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, AustraliaAbstract: High-dose potent statin therapy in ...
Ian Hamilton-Craig +3 more
doaj +2 more sources
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:Results of a 24week, double-blind, randomized Phase 3 trial [PDF]
, 2014 Background:Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy. Methods In a Phase 3, randomized, double-blind, double-dummy
Merlet, Laurence +9 more
core +1 more source
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia [PDF]
The Korean Journal of Internal Medicine, 2023 Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels.
Jeongmin Lee, Seung-Hwan Lee
doaj +1 more source
Frontiers in Immunology, 2022 Ankylosing spondylitis (AS) is a chronic inflammatory disease that causes spinal inflammation and fusion. Although the cause of AS is unknown, genetic factors (e.g., HLA-B27) and environmental factors (e.g., sex, age, and infection) increase the risk of ...
Jeonghyeon Moon +18 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 BackgroundStatins are the most widely prescribed medication to lower low-density lipoprotein cholesterol (LDL-c). However, a significant portion of patients are unable to tolerate them due to side effects, most commonly muscle related.
Natalie C. Ward +3 more
doaj +1 more source